SMC Update - July 2013
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Latanoprost preservative-free eye-drops (Monopost®) have been accepted for restricted use for the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension. The restriction limits use to those patients who have proven sensitivity to the preservative benzalkonium chloride.
Nomegestrol acetate/estradiol (Zoely®) has been rejected for use as an oral contraceptive. The manufacturer failed to make a submission.
Adalimumab (Humira®) has been accepted for restricted use in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17 years. The restriction limits use to specialist rheumatology services.
Adalimumab (Humira®) has been accepted for restricted use in the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy. The restriction limits use to specialists in paediatric gastroenterology.
Everolimus (Afinitor®) has been rejected as a treatment of hormone receptor-positive, human epidermal growth factor type 2 (HER2)/neu negative advanced breast cancer in combination with exemestane in postmenopausal women. The manufacturer failed to make a sufficiently robust economic case.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « ASA censures the Society of Homeopaths | Shingles vaccine information » |
Leave a Comment